

# Rheumatology IV

## REFERRAL FORM

FAX REFERRAL TO: +1(844) 277-0049

PHONE: +1(844) 650-5802



### 1 PATIENT'S INFORMATION (Complete or include demographic sheet)

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Gender: ☐ MALE ☐ FEMALE  
Address: \_\_\_\_\_ City/State/Zip: \_\_\_\_\_  
Primary Phone: \_\_\_\_\_ Email: \_\_\_\_\_ SSN: \_\_\_\_\_ Primary Language: \_\_\_\_\_  
Emergency Contact: \_\_\_\_\_ Relationship to Patient: \_\_\_\_\_ Phone: \_\_\_\_\_

### 2 INSURANCE (Please attach **IF AVAILABLE** a copy of the Patient's' insurance card(s) Front/ Back)

Primary Insurance: \_\_\_\_\_ Policy No: \_\_\_\_\_ Group: \_\_\_\_\_  
Primary RX Insurance: \_\_\_\_\_ ID No: \_\_\_\_\_ RX GRP: \_\_\_\_\_ RX BIN: \_\_\_\_\_ RX PCN: \_\_\_\_\_

### 3 DIAGNOSIS AND CLINICAL INFORMATION

First time receiving Therapy? ☐ Yes ☐ No If No, previous product used: \_\_\_\_\_ Last Dose Given: \_\_\_\_\_

#### Diagnosis (ICD-10):

- |   |  |
|---|--|
| <input type="checkbox"/> L40.50 Arthropathic Psoriasis, Unspecified                           | <input type="checkbox"/> M08.20 Systemic Juvenile Idiopathic Arthritis (SJIA)        |
| <input type="checkbox"/> L40.59 Other Psoriatic Arthropathy                                   | <input type="checkbox"/> M31.6 Giant Cell Arteritis (GCA)                            |
| <input type="checkbox"/> M06.9 Rheumatoid Arthritis, Unspecified                              | <input type="checkbox"/> M45.9 Non-Radiographic Axial Spondylarthritis (nr-axSpA)    |
| <input type="checkbox"/> M08.00 Unspecified Juvenile Rheumatoid Arthritis of Unspecified Site | <input type="checkbox"/> M45.A0 Ankylosing Spondylitis of Unspecified Sites in Spine |
| <input type="checkbox"/> M08.90 Polyarticular Juvenile Idiopathic Arthritis (PJIA)            | <input type="checkbox"/> Other: _____ Description: _____                             |

#### Patient Clinical Information:

Drug Allergies: \_\_\_\_\_ ☐ NKDA Ht: \_\_\_\_\_ in/cm Wt: \_\_\_\_\_ lbs/Kg

TB Test Date: \_\_\_\_\_ ☐ Positive(+) ☐ Negative(-) Hepatitis-B Test Date: \_\_\_\_\_ ☐ Positive(+) ☐ Non-Reactive(-)

Labs: Please fax copy of the following labs dated within 1 year of the patients referral request:

☐ CMP ☐ CBC w/ diff ☐ Hepatitis-(B) ☐ QuantiFERON-(QFT)/ T-Spot

### 4 PRESCRIPTION INFORMATION

ACCESS: ☐ IV ☐ PORT

**RX INFORMATION:** Our pharmacist will identify clinically appropriate brand *(Unless product is specifically specified at the time of referral)* and infusion rate per FDA guidelines. Clinically appropriate substitutions may be allowed based on availability or payor requirements. Round dose(s) to the nearest vial size. Official orders will be outlined with "May Infuse" +/- 3 days if scheduling needs arises, with insurance payor approval".

PRODUCT: ☐ Actemra ☐ Avsola ☐ Inflectra ☐ InFLIXimab ☐ Orencia ☐ Remicade ☐ Renflexis ☐ Simponi ARIA ☐ Other: \_\_\_\_\_

#### DOSE & DIRECTIONS

LOADING DOSE: \_\_\_\_\_

MAINTENANCE DOSE: \_\_\_\_\_

#### PRE/POST ORDERS:

MEDICATION	DIRECTION	QUANTITY	REFILLS
<input type="checkbox"/> SoluMedrol® (IV)	Give _____ mg prior to infusion via <input type="checkbox"/> IV push <input type="checkbox"/> diluted in _____ mL of NS over 30 min.	Quantity: <b>Q.S</b>	Refills: <b>PRN</b>
<input type="checkbox"/> Diphenhydramine: <input type="checkbox"/> PO <input type="checkbox"/> IV	Administer _____ mg 30-60 min Prior to Infusion. May repeat every _____ hours PRN.	Quantity: <b>Q.S</b>	Refills: <b>PRN</b>
<input type="checkbox"/> Acetaminophen (PO)	Administer _____ mg PO 30-60 min Prior to Infusion. May repeat every _____ hours PRN.	Quantity: <b>Q.S</b>	Refills: <b>PRN</b>
<input type="checkbox"/> Hydration: <input type="checkbox"/> 0.9% NaCL <input type="checkbox"/> LR	Infuse _____ mL of _____ solution <input type="checkbox"/> before <input type="checkbox"/> after infusion.	Quantity: <b>Q.S</b>	Refills: <b>PRN</b>

#### ANAPHYLAXIS PROTOCOL:

MEDICATION	DIRECTION	QUANTITY	REFILLS
<input checked="" type="checkbox"/> EPINEPHRINE (vial or autoinjector)	Administer IM for severe anaphylactic reaction. May repeat in 5-15 minutes <input type="checkbox"/> 0.3 mg (Wt > 30 kg) <input type="checkbox"/> 0.15 mg (Wt 15-30 kg) <input type="checkbox"/> 0.1 mg (Wt 7.5-15 kg)	Quantity: (x1) Vial or (x2) Pen(s)	Refills: <b>PRN</b>
<input checked="" type="checkbox"/> DIPHENHYDRAMINE (50mg/mL)	Administer via IM or slow IV push for severe anaphylactic reaction. <input type="checkbox"/> 50 mg (Wt > 30 kg) <input type="checkbox"/> 25 mg (Wt 15-30 kg) <input type="checkbox"/> 12.5mg (Wt 7.5-15kg)	Quantity: (x1) Vial(s)	Refills: <b>PRN</b>
<input checked="" type="checkbox"/> SODIUM CHLORIDE 0.9% (IV)	Infuse 500 mL IV as directed for severe anaphylactic reaction.	Quantity: <b>500 mL</b>	Refills: <b>PRN</b>

#### NURSING/ LABS/ INFUSION SUPPLIES:

☒ **NURSING:** Nursing visits with each infusion to establish venous access, administer medication, assess and monitor patient, provide education, and complete lab draws.

☒ **INFUSION SUPPLIES:** Diluent, infusion supplies, and infusion pump PRN for the reconstitution, administration, and disposal of medication.

**FLUSHING PROTOCOL:** ☒ Sodium chloride 0.9%, Up to 10 mL before/after medication, and/or PRN to maintain patency.

Heparin: ☐ 10 Units/mL ☐ 100 Units/mL, \_\_\_\_\_ as final flush and/or PRN to maintain patency

☒ **LABS:** [Dx code: Z79.899] Labs as follows, to be drawn annually by RN prior to infusion unless frequency is specified: every \_\_\_\_\_ month(s)

☐ CMP ☐ CBC w/ diff ☐ Hep-(B) ☐ Other: \_\_\_\_\_

☒ **LABS:** TB test shall be ordered at a frequency deemed appropriate and performed by an outside lab facility.

### 5 PRESCRIBER INFORMATION

Prescriber Name: \_\_\_\_\_ Title: ☐ MD ☐ DO ☐ ND ☐ PA ☐ APRN NPI: \_\_\_\_\_  
Address: \_\_\_\_\_ City/State/Zip: \_\_\_\_\_  
Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Contact Person: \_\_\_\_\_

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record.

I authorize IV Solutions RX and its representatives to act as an agent to initiate and execute the insurance prior authorization process for this prescription and any future refills of the same prescription for the patient listed above. I understand that I can revoke the designation at any time by providing written notice to IV Solutions RX.

**CONFIDENTIALITY NOTICE:** The information contained in this transmission may contain confidential information, including patient information protected by federal and state privacy laws. It is intended only for the use of the person(s) named above. If not the intended recipient, you are hereby notified that any review, dissemination, distribution, or duplication of this communication is strictly prohibited. If you are not the intended recipient, please contact the sender by reply email to [info@ivsolutionsrx.com](mailto:info@ivsolutionsrx.com) and destroy all copies of the original message.

Physicians signature \_\_\_\_\_

Date \_\_\_\_\_

**THANK YOU FOR YOU TRUSTING US WITH YOUR PATIENTS SPECIALTY CARE**

#welcome to our family